Abstract
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive-aged women. It is typically characterized by hyperandrogenism, chronic anovulation, and the presence of polycystic ovaries. Dermatologic manifestations commonly encountered in women with PCOS include hirsutism, acne vulgaris, and androgenic alopecia or female hair loss. This chapter reviews the treatments for these clinical manifestations that are attributed to androgen excess in women with PCOS.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28–38.e25.
Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7.
Mueller A, Cupisti S, Binder H, Hoffmann I, Kiesewetter F, Beckmann MW, et al. Endocrinological markers for assessment of hyperandrogenemia in hirsute women. Horm Res. 2007;67(1):35–41.
Loriaux DL. An approach to the patient with hirsutism. J Clin Endocrinol Metab. 2012;97(9):2957–68.
Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89(2):453–62.
Carmina E, Rosato F, Janni A, Rizzo M, Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab. 2006;91(1):2–6.
Chen W, Zouboulis CC, Orfanos CE. The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders. Dermatology. 1996;193(3):177–84.
Messenger AG. The control of hair growth: an overview. J Invest Dermatol. 1993;101(1 Suppl):4S–9.
Unluhizarci K, Kaltsas G, Kelestimur F. Non polycystic ovary syndrome-related endocrine disorders associated with hirsutism. Eur J Clin Invest. 2012;42(1):86–94.
Speiser PW. Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Endocrinol Metab Clin North Am. 2001;30(1):31–59. vi.
Trueb RM. Causes and management of hypertrichosis. Am J Clin Dermatol. 2002;3(9):617–27.
Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440–7.
DeUgarte CM, Woods KS, Bartolucci AA, Azziz R. Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J Clin Endocrinol Metab. 2006;91(4):1345–50.
Martin KA, Chang RJ, Ehrmann DA, Ibanez L, Lobo RA, Rosenfield RL, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(4):1105–20.
Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2012;18(2):146–70.
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456–88.
White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev. 2000;21(3):245–91.
Raj SG, Raj MH, Talbert LM, Sloan CS, Hicks B. Normalization of testosterone levels using a low estrogen-containing oral contraceptive in women with polycystic ovary syndrome. Obstet Gynecol. 1982;60(1):15–9.
Wiebe RH, Morris CV. Effect of an oral contraceptive on adrenal and ovarian androgenic steroids. Obstet Gynecol. 1984;63(1):12–4.
Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab. 2004;89(6):2817–23.
Dewis P, Petsos P, Newman M, Anderson DC. The treatment of hirsutism with a combination of desogestrel and ethinyl oestradiol. Clin Endocrinol. 1985;22(1):29–36.
Cullberg G, Hamberger L, Mattsson LA, Mobacken H, Samsioe G. Effects of a low-dose desogestrel-ethinylestradiol combination on hirsutism, androgens and sex hormone binding globulin in women with a polycystic ovary syndrome. Acta Obstet Gynecol Scand. 1985;64(3): 195–202.
Darney PD. The androgenicity of progestins. Am J Med. 1995;98(1A):104S–10.
Mathur R, Levin O, Azziz R. Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome. Ther Clin Risk Manag. 2008;4(2):487–92.
Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D, et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception. 2013;87(1):93–100.
Cumming DC. Use of spironolactone in treatment of hirsutism. Cleveland Clinic J Med. 1990;57(3):285–7.
Serafini PC, Catalino J, Lobo RA. The effect of spironolactone on genital skin 5 alpha-reductase activity. J Steroid Biochem. 1985;23(2):191–4.
Brown J, Farquhar C, Lee O, Toomath R, Jepson RG. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev. 2009 (2):CD000194.
Karakurt F, Sahin I, Guler S, Demirbas B, Culha C, Serter R, et al. Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study. Adv Ther. 2008;25(4):321–8.
Wong IL, Morris RS, Chang L, Spahn MA, Stanczyk FZ, Lobo RA. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab. 1995;80(1):233–8.
Brahm J, Brahm M, Segovia R, Latorre R, Zapata R, Poniachik J, et al. Acute and fulminant hepatitis induced by flutamide: case series report and review of the literature. Ann Hepatol. 2011;10(1):93–8.
Van der Spuy ZM, le Roux PA. Cyproterone acetate for hirsutism. Cochrane Database Syst Rev. 2003 (4):CD001125.
Azziz R, Ochoa TM, Bradley Jr EL, Potter HD, Boots LR. Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study. J Clin Endocrinol Metab. 1995;80(12):3406–11.
Falsetti L, Pasinetti E, Ceruti D. Gonadotropin-releasing hormone agonist (GnRH-A) in hirsutism. Acta Eur Fertil. 1994;25(5):303–6.
Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774–800.
Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001;86(4):1626–32.
Frank-Raue K, Junga G, Raue F, Vecsei P, Ziegler R. Therapy of hirsutism in females with adrenal enzyme defects of steroid hormone biosynthesis: comparison of dexamethasone with cyproterone acetate. Klin Wochenschr. 1990;68(12):597–601. Therapie des Hirsutismus bei Frauen mit adrenalen Enzymdefekten der Steroidhormonbiosynthese: Vergleich von Dexamethason mit Cyproteronacetat.
Carmina E, Lobo RA. The addition of dexamethasone to antiandrogen therapy for hirsutism prolongs the duration of remission. Fertil Steril. 1998;69(6):1075–9.
Hamzavi I, Tan E, Shapiro J, Lui H. A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women. J Am Acad Dermatol. 2007;57(1):54–9.
Smith SR, Piacquadio DJ, Beger B, Littler C. Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial. Dermatol Surg. 2006;32(10):1237–43.
Olsen EA. Methods of hair removal. J Am Acad Dermatol. 1999;40(2 Pt 1):143–55. quiz 56–7.
McGill DJ, Hutchison C, McKenzie E, McSherry E, Mackay IR. Laser hair removal in women with polycystic ovary syndrome. J Plast Reconstr Aesthet Surg. 2007;60(4):426–31.
Clayton WJ, Lipton M, Elford J, Rustin M, Sherr L. A randomized controlled trial of laser treatment among hirsute women with polycystic ovary syndrome. Br J Dermatol. 2005;152(5):986–92.
Vachiramon V, Brown T, McMichael AJ. Patient satisfaction and complications following laser hair removal in ethnic skin. J Drugs Dermatol. 2012;11(2):191–5.
Hovenic W, DeSpain J. Laser hair reduction and removal. Facial Plastic Surg Clin North Am. 2011;19(2):325–33.
Wagner Jr RF. Physical methods for the management of hirsutism. Cutis. 1990;45(5):319–21. 25-6.
Harris K, Ferguson J, Hills S. A comparative study of hair removal at an NHS hospital: luminette intense pulsed light versus electrolysis. J Dermatolog Treat. 2012. Early Online: 1–5.
Chuan SS, Chang RJ. Polycystic ovary syndrome and acne. Skin Therapy Lett. 2010;15(10):1–4.
Kelekci KH, Kelekci S, Incki K, Ozdemir O, Yilmaz B. Ovarian morphology and prevalence of polycystic ovary syndrome in reproductive aged women with or without mild acne. Int J Dermatol. 2010;49(7):775–9.
Imperato-McGinley J, Gautier T, Cai LQ, Yee B, Epstein J, Pochi P. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab. 1993;76(2):524–8.
Volpe A, Silferi M, Mauri A, Deiana P, Angioni S, Grasso A, et al. Efficacy on hyperandrogenism and safety of a new oral contraceptive biphasic formulation containing desogestrel. Eur J Obstet Gynecol Reprod Biol. 1994;53(3):205–9.
Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, Jorizzo JL. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol. 1997;89(4):615–22.
Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2012;7:CD004425.
Koltun W, Maloney JM, Marr J, Kunz M. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 mug plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis. Eur J Obstet Gynecol Reprod Biol. 2011;155(2):171–5.
Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis. 2004;74(2):123–30.
Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49 (1 Suppl):S1–37.
Strauss JS, Krowchuk DP, Leyden JJ, Lucky AW, Shalita AR, Siegfried EC, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56(4):651–63.
Del Rosso JQ, Kim G. Optimizing use of oral antibiotics in acne vulgaris. Dermatol Clin. 2009;27(1):33–42.
Anderson KC, Schwartz MD, Lieu SO. Antibiotics and OC effectiveness. JAAPA. 2013;26(1):11.
Yemisci A, Gorgulu A, Piskin S. Effects and side-effects of spironolactone therapy in women with acne. J Eur Acad Dermatol Venereol. 2005;19(2):163–6.
George R, Clarke S, Thiboutot D. Hormonal therapy for acne. Semin Cutaneous Med Surg. 2008;27(3):188–96.
Moghetti P, Toscano V. Treatment of hirsutism and acne in hyperandrogenism. Best Pract Res Clin Endocrinol Metab. 2006;20(2):221–34.
Zeichner JA. Optimizing topical combination therapy for the treatment of acne vulgaris. J Drugs Dermatol. 2012;11(3):313–7.
Tanghetti E, Dhawan S, Green L, Ling M, Downie J, Germain MA, et al. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris. J Drugs Dermatol. 2011;10(7):783–92.
Camacho-Martinez FM. Hair loss in women. Semin Cutaneous Med Surg. 2009;28(1):19–32.
Birch MP, Messenger JF, Messenger AG. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol. 2001;144(2):297–304.
Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med. 1999;341(7):491–7.
Chartier MB, Hoss DM, Grant-Kels JM. Approach to the adult female patient with diffuse nonscarring alopecia. J Am Acad Dermatol. 2002;47(6):809–18. quiz 18–20.
Ross EK, Tan E, Shapiro J. Update on primary cicatricial alopecias. J Am Acad Dermatol. 2005;53(1):1–37. quiz 8–40.
Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977;97(3):247–54.
Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6(2):130–6.
Jacobs JP, Szpunar CA, Warner ML. Use of topical minoxidil therapy for androgenetic alopecia in women. Int J Dermatol. 1993;32(10):758–62.
DeVillez RL, Jacobs JP, Szpunar CA, Warner ML. Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Arch Dermatol. 1994;130(3):303–7.
Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541–53.
Shum KW, Cullen DR, Messenger AG. Hair loss in women with hyperandrogenism: four cases responding to finasteride. J Am Acad Dermatol. 2002;47(5):733–9.
Iorizzo M, Vincenzi C, Voudouris S, Piraccini BM, Tosti A. Finasteride treatment of female pattern hair loss. Arch Dermatol. 2006;142(3):298–302.
Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril. 2003;79(1):91–5.
Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005;152(3):466–73.
Desai S, Mahmoud BH, Bhatia AC, Hamzavi IH. Paradoxical hypertrichosis after laser therapy: a review. Dermatol Surg. 2010;36(3):291–8.
Rangwala S, Rashid RM. Alopecia: a review of laser and light therapies. Dermatol Online J. 2012;18(2):3.
Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol. 2008;59(4):547–66. quiz 67–8.
Avram M, Rogers N. Contemporary hair transplantation. Dermatol Surg. 2009;35(11):1705–19.
Caroli S, Pathomvanich D, Amonpattana K, Kumar A. Current status of hair restoration surgery. Int Surg. 2011;96(4):345–51.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
McAvey, B., Lieman, H. (2014). Managing the PCOS-Related Symptoms of Hirsutism, Acne, and Hair Loss. In: Pal, L. (eds) Polycystic Ovary Syndrome. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8394-6_13
Download citation
DOI: https://doi.org/10.1007/978-1-4614-8394-6_13
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-8393-9
Online ISBN: 978-1-4614-8394-6
eBook Packages: MedicineMedicine (R0)